510(k) device
RelieVRx (Pico G3)
Appliedvr · Virtual Reality Behavioral Therapy Device For Pain Relief (QRA, Class II) · First FDA decision Dec 4, 2024, newest Aug 13, 2025Chronic pain
Last checked: Nov 19, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
2
510(k) pathway
Device trials
5
Naming "RelieVRx"
MAUDE reports
0
Brand "RelieVRx", since 2015
PubMed studies
9
Mentioning "RelieVRx"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing RelieVRx (Pico G3)
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 2 of 2 decisions filed under this name.
- RelieVRx (Pico G3)510(k)
K251519 · Decided Aug 13, 2025 · 89 days after receipt
Device type: Virtual Reality Behavioral Therapy Device For Pain Relief (QRA) · Neurology & Neurosurgery
- RelieVRx510(k)
K243417 · Decided Dec 4, 2024 · 30 days after receipt
Device type: Virtual Reality Behavioral Therapy Device For Pain Relief (QRA) · Neurology & Neurosurgery
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- Intensive Behavioral Therapy for ObesityNational analysisReview closedCAG-00423NUpdated Sep 18, 2026
- Intensive Behavioral Therapy for Cardiovascular DiseaseNational analysisReview closedCAG-00424NUpdated Sep 18, 2026
- Intensive Behavioral Therapy for ObesityNational determinationOn the books210.12Updated Dec 2, 2024
- Intensive Behavioral Therapy for Cardiovascular DiseaseNational determinationOn the books210.11Updated Dec 2, 2024
Clinical trials
Device studies on ClinicalTrials.gov that name "RelieVRx", any status and sponsor, newest update first.
University of Maryland, BaltimoreAcademic, hospital or other
NCT06214923 · 78 participants (planned) · Start Apr 9, 2024 · Primary completion May 30, 2026
Device: RelieVRx; Sham-VR · For: Pain; Virtual Reality; Placebo and 1 more
Sites: Baltimore, Maryland · 2 sites in all
University of Southern CaliforniaAcademic, hospital or other
NCT05585905 · 20 participants · Start Mar 17, 2023 · Primary completion Jun 30, 2024
Device: Virtual Reality · For: Behavior, Child; Anxiety, Dental
Sites: Long Beach, California; Los Angeles, California
University of Maryland, BaltimoreAcademic, hospital or other
NCT06248216 · 30 participants (planned) · Start Dec 4, 2024 · Primary completion Apr 2027
Device: Relievrx · For: Cancer; Cancer Pain; Virtual Reality
Sites: Baltimore, Maryland · 2 sites in all
2 more trials with a free account
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "RelieVRx", and for the whole product code for context.
This brand
0 reports: 0 malfunction, 0 injury, 0 death
Whole product code QRA
0 reports: 0 malfunction, 0 injury, 0 death
Newest reports for this brand
No MAUDE reports name this brand.
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "RelieVRx"[tiab]. The summary above synthesizes these.
- In-Home Virtual Reality Program for Chronic Lower Back Pain: A Randomized Sham-Controlled Effectiveness Trial in a Clinically Severe and Diverse Sample.
Maddox T, Oldstone L, Sparks CY, et al. · Mayo Clin Proc Digit Health · 2023
- Virtual Reality for Subacute Pain After Orthopedic Traumatic Musculoskeletal Injuries: A Mixed Methods Pilot Study.
Mace RA, Brewer JR, Cohen JE, et al. · Clin J Pain · 2024
- Digital Therapeutics (DTx) Expand Multimodal Treatment Options for Chronic Low Back Pain: The Nexus of Precision Medicine, Patient Education, and Public Health.
Rohaj A, Bulaj G · Healthcare (Basel) · 2023
- From innovation to implementation: a case report on virtual reality for chronic pain and psychological well-being in clinical practice.
Rivera-Rivera N, Lopez J, Haberland N, et al. · Front Psychiatry · 2026Case Reports
- Virtual Reality-Based Pain Modulation in Subacute Musculoskeletal Injury: Functional Near-Infrared Spectroscopy Study of Neural and Behavioral Correlates.
Mace RA, Wu Z, Sieberg CB, et al. · JMIR Serious Games · 2026
- Perspective: The Promise of Virtual Reality as an Immersive Therapeutic.
Maddox T, Sparks CY, Oldstone L, et al. · J Med Ext Real · 2024
- Sociodemographic Predictors of Clinical Effectiveness, Therapeutic Program Engagement, and Device Usability for an In-Home Virtual Reality Program for Chronic Low Back Pain: Secondary Analysis of a Randomized Controlled Trial.
Maddox T, Oldstone L, Sackman J, et al. · J Med Ext Real · 2024
- Twelve-month results for a randomized sham-controlled effectiveness trial of an in-home skills-based virtual reality program for chronic low back pain.
Maddox T, Oldstone L, Sackman J, et al. · Pain Rep · 2024
- Virtual Reality Respiratory Biofeedback in an Outpatient Pediatric Pain Rehabilitation Program: Mixed Methods Pilot Study.
Recker K, Silliman J, Gifford K, et al. · JMIR Rehabil Assist Technol · 2025
Other devices of this type
Also filed under product code QRA.
- VrntCognifisense, Inc. · 510(k) 2026
- Smileyscope System (Therapy Mode)Smileyscope Holding, Inc. · 510(k) 2023
- EaseVRxAppliedvr, Inc. · De Novo 2021
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.